|
1
|
Enemoto Y, Enomoto K, Uchino S, Shibuya H,
Watanabe S and Noguchi S: Clinical features, treatment and
long-term outcome of papillary thyroid cancer in children and
adolescents without radiation exposure. World J Surg. 36:1241–1246.
2012. View Article : Google Scholar
|
|
2
|
Bleyer A, Leary O, Barr M and Ries LAG:
Cancer epidemiology in older adolescents and young adults 15 to 29
years of age, including SEER incidence and survival 1975-2000.
National Cancer Institute; Bethesda, MD: (NIH Pub No. 06-5767).
2006
|
|
3
|
Ministry of Health, National Cancer
Institute, Brazilian Society of Pediatric Oncology: Childhood and
adolescents cancer in Brazil: Data from mortality and
population-based registries. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//childhood-adolescent-cancer-2009.pdf.
|
|
4
|
Holmes L, Hossain J and Opara F: Pediatric
thyroid carcinoma incidence and temporal trends in the USA
(1973-2007): Race or shifting diagnostic paradigm? ISRN Oncol.
2012:9061972012.PubMed/NCBI
|
|
5
|
Golpanian S, Perez EA, Tashiro J, Lew JI,
Sola JE and Hogan AR: Pediatric papillary thyroid carcinoma:
Outcomes and survival predictors in 2504 patients. Pedriatr Surg
Int. 32:201–208. 2016. View Article : Google Scholar
|
|
6
|
Vaisman F, Corbo R and Vaisman M: Thyroid
carcinoma in children and adolescents-systematic review of the
literature. J Thyroid Res. 845362:2011.
|
|
7
|
Park S, Jeong JS, Ryu HR, Lee CR, Park JH,
Kang SW, Jeong JJ, Nam KH, Chung KY and Park CS: Differentiated
thyroid carcinoma of children and adolescents: 27-year experience
in the Yonsei University Health System. J Korean Med Sci.
28:693–699. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Paulson VA, Rudzinski ER and Hawkins DS:
Thyroid cancer in the pediatric population. Genes (Basel).
10:7232019. View Article : Google Scholar
|
|
9
|
Ceolin L, Duval MADS, Benini AF, Ferreira
CV and Maia AL: Medullary thyroid carcinoma beyond surgery:
Advances, challenges, and perspectives. Endocr Relat Cancer.
26:R499–R518. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Markovina S, Grigsby PW, Schwarz JK,
DeWees T, Moley JF, Siegel BA and Perkins SM: Treatment approach,
surveillance, and outcome of well-differentiated thyroid cancer in
childhood and adolescence. Thyroid. 24:1121–1126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tuttle RM, Vaisman F and Tronko MD:
Clinical presentation and clinical outcomes in Chernobyl-related
pediatric thyroid cancers: What do we know now? What can we expect
in the future? Clin Oncol (R Coll Radiol). 23:268–275. 2011.
View Article : Google Scholar
|
|
12
|
Massimino M, Evens DB, Podda M, Spinelli
C, Collini P, Pizzi N and Bleyer A: Thyroid cancer in adolescents
and young adults. Pediatr Blood Cancer. 65:e270252018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Francis GL, Waguespack SG, Bauer AJ,
Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID,
Luster M, et al: Management guidelines for children with thyroid
nodules and differentiated thyroid cancer. Thyroid. 25:716–759.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Waguespack SG, Sherman SI, Williams MD,
Clayman GL and Herzog CE: The successful use of Sorafenib to treat
pediatric papillary thyroid carcinoma. Thyroid. 19:407–412. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iyer P, Mayer JLR and Ewig JM: Response to
Sorafenib in a pediatric patient with papillary thyroid carcinoma
with diffuse nodular pulmonary disease requiring mechanical
ventilation. Thyroid. 24:169–174. 2014. View Article : Google Scholar
|
|
16
|
Higuchi Y, Motoky T, Ishida H, Kanamitsu
K, Washio K, Oyama T, Noda T, Tsurumaru Y, Okada A, Tsukahara H and
Shimada A: Sorafenib treatment for papillary thyroid carcinoma with
diffuse lung metastases in a child with autism spectrum disorder: A
Case Report. BMC Cancer. 17:7752017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mahajan P, Dawrant J, Kheradpour A,
Quintanilla NM, Lopez ME, Orth RC, Athanassaki I and Venkatramani
R: Response to Lenvatinib in children with papillary thyroid
carcinoma. Thyroid. 28:1450–1454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Welch Dinauer CA, Tuttle RM, Robie DK,
McClellan DR, Svec RL, Adair C and Francis GL: Clinical features
associated with metastasis and recurrence of differentiated thyroid
cancer in children, adolescents and young adults. Clin Endocrinol
(Oxf). 49:619–628. 1998. View Article : Google Scholar
|
|
19
|
Vassilopoulou-Sellin R, Klein MJ, Smith
TH, Samaan NA, Frankenthaler RA, Goepfert H, Cangir A and Haynie
TP: Pulmonary metastases in children and young adults with
differentiated thyroid cancer. Cancer. 71:1348–1352. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Demidchik YE, Demidchik EP, Reiners C,
Biko J, Mine M, Saenko VA and Yamashita S: Comprehensive clinical
assessment of 740 cases of surgically treated thyroid cancer in
children of Belarus. Ann Surg. 243:525–532. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Newman KD, Black T, Heller G, Azizkhan RG,
Holcomb GW III, Sklar C, Vlamis V, Haase GM and La Quaglia MP:
Differentiated thyroid cancer: Determinants of disease progression
in patients <21 years of age at diagnosis: A report from the
surgical discipline committee of the Children's cancer group. Ann
Surg. 227:533–541. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wada N, Sugino K, Mimura T, Nagahama M,
Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Rino Y, et
al: Pediatric differentiated thyroid carcinoma in stage I: Risk
factor analysis for disease free survival. BMC Cancer. 9:3062009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jarzab B, Handkiewicz Junak D, Wloch J,
Kalemba B, Roskosz J, Kukulska A and Puch Z: Multivariate analysis
of prognostic factors for differentiated thyroid carcinoma in
children. Eur J Nucl Med. 27:833–841. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wada N, Sugino K, Mimura T, Nagahama M,
Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Yukawa N,
et al: Treatment strategy of papillary thyroid carcinoma in
children and adolescents: Clinical significance of the initial
nodal manifestation. Ann Surg Oncol. 16:3442–3449. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koo JS, Hong S and Park CS: Diffuse
sclerosing variant is a major subtype of papillary thyroid
carcinoma in the young. Thyroid. 19:1225–1231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugg SL, Ezzat S, Rosen IB, Freeman JL and
Asa SL: Distinct multiple RET/PTC gene rearrangements in multifocal
papillary thyroid neoplasia. J Clin Endocrinol Metab. 83:4116–4122.
1998.PubMed/NCBI
|
|
28
|
Zaydfudim V, Feurer ID, Griffin MR and
Phay JE: The impact of lymph node involvement on survival in
patients with papillary and follicular thyroid carcinoma. Surgery.
144:1070–1078. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Leboulleux S, Baudin E, Hartl DW, Travagli
JP and Schlumberger M: Follicular cell-derived thyroid cancer in
children. Horm Res. 63:145–151. 2005.PubMed/NCBI
|
|
30
|
Pawelczak M, David R, Franklin B, Kessler
M, Lam L and Shah B: Outcomes of children and adolescents with
well-differentiated thyroid carcinoma and pulmonary metastases
following 131I Treatment: A systematic review. Thyroid.
20:1095–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sabra MM, Grewal RK, Tala H, Larson SM and
Tuttle RM: Clinical outcomes following empiric radioiodine therapy
in patients with structurally identifiable metastatic follicular
cell-derived thyroid carcinoma with negative diagnostic but
positive post-therapy 131I whole-body scans. Thyroid. 22:877–883.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zanella AB, Scheffel RS, Nava CF, Golbert
L, Meyer ELS, Punales M, Gonçalves I, Dora JM and Maia AL: Dynamic
risk stratification in the follow-up of children and adolescents
with differentiated thyroid cancer. Thyroid. 28:1285–1292. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scheffel RS, Zanella AB, Antunes D, Dora
JM and Maia AL: Low recurrence rates in a cohort of differentiated
thyroid carcinoma patients: A referral center experience. Thyroid.
25:883–889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park S, Kim WG, Song E, Oh HS, Kim M, Kwon
H, Jeon MJ, Kim TY, Shong YK and Kim WB: Dynamic risk
stratification for predicting recurrence in patients with
differentiated thyroid cancer treated without radioactive iodine
remnant ablation therapy. Thyroid. 27:524–530. 2017. View Article : Google Scholar
|
|
35
|
Krajewska J, Jarzab M, Czarniecka A,
Roskosz J, Kukulska A, Handkiewicz-Junak D, Puch Z, Wygoda Z,
Paliczka-Cieślik E, Kropińska A, et al: Ongoing risk stratification
for differentiated thyroid cancer (DTC)-stimulated serum
thyroglobulin (Tg) before radioiodine (RAI) ablation, the most
potent risk factor of cancer recurrence in M0 patients. Endokrynol
Pol. 67:2–11. 2016. View Article : Google Scholar
|
|
36
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association Management
Guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroi. Thyroid.
26:1–133. 2016. View Article : Google Scholar :
|
|
37
|
Vaisman F, Bulzico D, Pessoa CHCN,
Bordallo MA, Mendonça UB, Dias FL, Coeli CM, Corbo R and Vaisman M:
Prognostic factors of a good response to initial therapy in
children and adolescents with differentiated thyroid cancer.
Clinics (Sao Paulo). 66:281–286. 2011. View Article : Google Scholar
|
|
38
|
Mihailovic J, Nikoletic K and Srbovan D:
Recurrent disease in juvenile differentiated thyroid carcinoma:
Prognostic factors, treatments, and outcomes. J Nucl Med.
55:710–717. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pires BP, Alves PA, Bordallo MA, Bulzico
DA, Lopes FPPL, Farias T, Dias F, Lima RA, Gisler ICS, Coeli CM, et
al: Prognostic factors for early and long-term remission in
pediatric differentiated thyroid cancer: The role of sex, age,
clinical presentation and the newly proposed American Thyroid
Association risk stratification system. Thyroid. 26:1480–1487.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Verburg FA, Mäder U, Luster M, Hänscheid H
and Reiners C: Determinants of successful ablation and complete
remission after total thyroidectomy and I131 therapy of pediatric
differentiated thyroid cancer. Eur J Nucl Med Mol Imaging.
42:1390–1398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rosário PW, Ward LS, Carvalho GA, Graf H,
Maciel RM, Maciel LM, Maia AL and Vaisman M; Sociedade Brasileira
de Endocrinologia e Metabologia: Thyroid nodules and differentiated
thyroid cancer: Update on the Brazilian consensus. Arq Bras
Endocrinol Metabol. 57:240–264. 2013.In En, Portuguese. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hannequin P, Liehn JC and Delisle MJ:
Multifactorial analysis of survival in thyroid cancer. Pitfalls of
applying the results of published studies to another population.
Cancer. 58:1749–175. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
DeGroot LJ, Kaplan EL, Straus FH and
Shukla MS: Does the method of management of papillary thyroid
carcinoma make a difference in outcome? World J Surg. 18:123–130.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tuttle RM, Morris LF, Haugen B, et al:
Thyroid-Differentiated and Anaplastic Carcinoma (Chapter 73). AJCC
Cancer Staging Manual. Amin MB, Edge S, Greene F, et al: 8th
edition. Springer International Publishing; New York, NY: 2017,
View Article : Google Scholar
|
|
45
|
Tala H and Tuttle RM: Contemporary
post-surgical management of differentiated thyroid carcinoma. Clin
Oncol (R Coll Radiol). 22:419–429. 2010. View Article : Google Scholar
|
|
46
|
Tuttle RM, Tala H, Shah J, Leboeuf R,
Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA and Shaha A:
Estimating risk of recurrence in differentiated thyroid cancer
after total thyroidectomy and radioactive iodine remnant ablation:
Using response to therapy variables to modify the initial estimates
predicted by the new American Thyroid Association Staging System.
Thyroid. 20:1341–1349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Momesso DP and Tuttle RM: Update on
differentiated thyroid cancer staging. Endocrinol Metab Clin North
Am. 43:401–421. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Vaisman F, Momesso D, Bulzico DA, Pessoa
CH, Dias F, Corbo R, Vaisman M and Tuttle RM: Spontaneous remission
in thyroid cancer patients after biochemical incomplete response to
initial therapy. Clin Endocrinol (Oxf). 77:132–138. 2012.
View Article : Google Scholar
|
|
49
|
Lazar L, Lebhental Y, Segal K, Steinmetz
A, Strenov Y, Cohen M, Yaniv I, Yackobovitch-Gavan M and Phillip M:
Pediatric thyroid cancer: Post-operative classifications and
response-to-initial-therapy as prognostic factors. J Clin
Endocrinol Metab. 101:1970–1979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sung TY, Jeon MJ, Lee YH, Lee YM, Kwon H,
Yoon JH, Chung KW, Kim WG, Song DE and Hong SJ: Initial and dynamic
risk stratification of pediatric patients with differentiated
thyroid cancer. J Clin Endocrinol Metab. 102:793–800. 2017.
|
|
51
|
Mazzaferri EL, Robbins RJ, Spencer CA,
Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper
DS, Braunstein GD, et al: A consensus report of the role of serum
thyroglobulin as a monitoring method for low-risk patients with
papillary thyroid carcinoma. J Clin Endocrinol Metab. 88:1433–1441.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hanscheid H, Verburg FA, Biko J, Diessl S,
Demidchik YE, Drozd V and Reiners C: Success of the post-operative
131I therapy in young Belarusian patients with differentiated
thyroid cancer after Chernobyl depends on the radiation absorbed
dose to the blood and the thyroglobulin level. Eur J Nucl Med Mol
Imaging. 38:1296–1302. 2011. View Article : Google Scholar
|
|
53
|
Zanella A, Scheffel RS, Pasa MW, Dora JM
and Maia AL: Role of post-operative stimulated thyroglobulin as
prognostic factor for differentiated thyroid cancer in children and
adolescents. Thyroid. 27:787–792. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu L, Zhang X, Tian T, Huang R and Liu B:
Prognostic value of pre-ablation stimulated thyroglobulin in
children and adolescents with differentiated thyroid cancer.
Thyroid. 30:1017–1024. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Verburg FA, Luster M, Cupini C, Chiovato
L, Duntas L, Elisei R, Feldt-Rasmussen U, Rimmele H, Seregni E,
Smit JW, et al: Implications of thyroglobulin antibody positivity
in patients with differentiated thyroid cancer: A clinical position
statement. Thyroid. 23:1211–1225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Spencer CA: Clinical review: Clinical
utility of thyroglobulin antibody (TgAb) measurements for patients
with differentiated thyroid cancers (DTC)). J Clin Endocrinol
Metab. 96:3615–3627. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Spencer CA, Takeuchi M, Kazarosyan M, Wang
CC, Guttler RB, Singer PA, Fatemi S, LoPresti JD and Nicoloff JT:
Serum thyroglobulin autoantibodies: Prevalence, influence on serum
thyroglobulin measurement, and prognostic significance in patients
with differentiated thyroid carcinoma. J Clin Endocrinol Metab.
83:1121–1127. 1998.PubMed/NCBI
|
|
58
|
Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY,
Kim JM, Ryu JS, Gong G, Hong SJ and Shong YK: Change of serum
antithyroglobulin antibody levels is useful for prediction of
clinical recurrence in thyroglobulin-negative patients with
differentiated thyroid carcinoma. J Clin Endocrinol Metab.
93:4683–4689. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chiovato L, Latrofa F, Braverman LE,
Pacini F, Capezzone M, Masserini L, Grasso L and Pinchera A:
Disappearance of humoral thyroid autoimmunity after complete
removal of thyroid antigens. Ann Intern Med. 139:346–351. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xing M, Alzahrani AS, Carson KA, Viola D,
Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, et al:
Association between BRAF V600E mutation and mortality in patients
with papillary thyroid cancer. JAMA. 309:1493–1501. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tufano RP, Teixeira GV, Bishop J, Carson
KA and Xing M: BRAF mutation in papillary thyroid cancer and its
value in tailoring initial treatment: A systematic review and
meta-analysis. Medicine (Baltimore). 91:274–286. 2012. View Article : Google Scholar
|
|
62
|
Bauer AJ: Molecular genetics of thyroid
cancer in children and adolescents. Endocrinol Metab Clin North Am.
46:389–403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hsiao SJ and Nikiforov YE: Molecular
approach to thyroid cancer diagnosis. Endocr Relat Cancer.
21:T301–T313. 2014.PubMed/NCBI
|
|
64
|
Cancer Genome Atlas Research Network:
Integrated genomic characterization of papillary thyroid carcinoma.
Cell. 159:676–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Nikiforov YE, Rowland JM, Bove KE,
Monforte-Munoz H and Fagin JA: Distinct pattern of RET oncogene
rearrangements in morphological variants of radiation-induced and
sporadic thyroid papillary carcinomas in children. Cancer Res.
57:1690–1694. 1997.PubMed/NCBI
|
|
66
|
Fenton C, Anderson J, Lukes Y, Dinauer CA,
Tuttle RM and Francis GL: Ras mutations are uncommon in sporadic
thyroid cancer in children and Young adults. J Endocrinol Invest.
22:781–789. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fenton C, Lukes Y, Nicholson D, Dinauer
CA, Francis GL and Tuttle RM: The RET/PTC mutations are common in
sporadic papillary thyroid carcinoma of Children and young adults.
J Clin Endocrinol Metab. 85:1170–1175. 2000.PubMed/NCBI
|
|
68
|
Kumagai A, Namba H, Saenko VA, Ashizawa K,
Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, et al:
Low frequency of BRAF T1796A mutation in childhood thyroid
carcinomas. J Clin Endocrinol Metab. 89:4280–4284. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Penko K, Livezey J, Fenton C, Patel A,
Nicholson D, Flora M, Oakley K, Tuttle RM and Francis G: BRAF
mutations are uncommon in papillary thyroid cancer of Young
patients. Thyroid. 15:320–325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Nikiforova MN, Ciampi R, Salvatore G,
Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI,
Tronko MD, et al: Low prevalence of BRAF mutations in
radiation-induced thyroid tumors in contrast to sporadic papillary
carcinomas. Cancer Lett. 209:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Rosenbaum E, Hosler G, Zahurak M, Cohen Y,
Sidransky D and Westra WH: Mutational activation of BRAF is not a
major event in sporadic childhood papillary thyroid carcinoma. Mod
Pathol. 18:898–902. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sassolas G, Hafdi-Nejjari Z, Ferraro A,
Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger
N and Fusco A: Oncogenic alterations in papillary thyroid cancers
of young patients. Thyroid. 22:17–26. 2012. View Article : Google Scholar
|
|
73
|
Ricarte-Filho JC, Li S, Garcia-Rendueles
ME, Montero-Conde C, Voza F, Knauf JA, Heguy A, Viale A, Bogdanova
T, Thomas GA, et al: Identification of kinase fusion oncogenes in
post-Chernobyl radiation-induced thyroid cancers. J Clin Invest.
123:4935–4944. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Henke LE, Perkins SM, Pfeifer JD, Ma C,
Chen Y, DeWees T and Grigsby PW: BRAF V600E mutational status in
pediatric thyroid cancer. Pediatr Blood Cancer. 61:1168–1172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Givens DJ, Buchmann LO, Agarwal AM,
Grimmer JF and Hunt JP: BRAF V600E does not predict aggressive
features of pediatric papillary thyroid carcinoma. Laryngoscope.
24:E389–E393. 2014. View Article : Google Scholar
|
|
76
|
Prasad ML, Vyas M, Horne MJ, Virk RK,
Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER,
Udelsman R, et al: NTRK fusion oncogenes in pediatric papillary
thyroid carcinoma in northeast United Sates. Cancer. 122:1097–1107.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Alzahrani AS, Qasem E, Murugan AK,
Al-Hindi HN, AlKhafaji D, Almohanna M, Xing M, Alhomaidah D and
AlSwailem M: Uncommon TERT promoter mutations in pediatric thyroid
cancer. Thyroid. 26:235–241. 2016. View Article : Google Scholar
|
|
78
|
Nikita ME, Jiang W, Cheng SM, Hantash FM,
McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM and
Newfield RS: Mutational analysis in pediatric thyroid cancer and
correlations with age, ethnicity and clinical presentation.
Thyroid. 6:227–234. 2016. View Article : Google Scholar
|
|
79
|
Onder S, Ozturk Sari S, Yegen G, Sormaz
IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y and
Mete O: Classic architecture with multicentricity and local
recurrence, and absence of TERT promoter mutations are correlates
of BRAF (V600E) harboring pediatric papillary thyroid carcinomas.
Endocr Pathol. 27:153–161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Gertz RJ, Nikiforov Y, Rehrauer W,
McDaniel L and Lloyd RV: Mutation in BRAF and other members of the
MAPK pathway in papillary thyroid carcinoma in the pediatric
population. Arch Pathol Lab Med. 140:134–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ballester LY, Sarabia SF, Sayeed H, Patel
N, Baalwa J, Athanassaki I, Hernandez JA, Fang E, Quintanilla NM,
Roy A and López-Terrada DH: Integrating molecular testing in the
diagnosis and management of children with thyroid lesions. Pediatr
Dev Pathol. 19:94–100. 2016. View Article : Google Scholar
|
|
82
|
Picarsic JL, Buryk MA, Ozolek J,
Ranganathan S, Monaco SE, Simons JP, Witchel SF, Gurtunca N, Joyce
J, Zhong S, et al: Molecular characterization of sporadic pediatric
thyroid carcinoma with the DNA/RNA Thyro/Seq v2 next-generation
sequencing assay. Pediatr Dev Pathol. 19:115–122. 2016. View Article : Google Scholar
|
|
83
|
Cordioli MI, Moraes L, Bastos AU, Besson
P, Alves MTS, Delcelo R, Monte O, Longui C, Cury AN and Cerutti JM:
Fusion oncogenes are the main genetic events found in the sporadic
papillary thyroid carcinomas from children. Thyroid. 27:182–188.
2017. View Article : Google Scholar
|
|
84
|
Geng J, Wang H, Liu Y, Tai J, Jin Y, Zhang
J, He L, Fu L, Qin H, Song Y, et al: Correlation between BRAF V600E
mutation and clinicopathological features in pediatric papillary
thyroid carcinoma. Sci China Life Sci. 60:729–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Poyrazoglu S, Bundak R, Bas F, Yeğen G,
Şanlı Y and Darendeliler F: Clinicopathological characteristics of
papillary thyroid cancer in children with emphasis on pubertal
status and association with BRAFV600E mutation. J Clin
Res Pedriatr Endocrinolol. 9:185–193. 2017. View Article : Google Scholar
|
|
86
|
Hardee S, Prasad ML, Hui P, Dinauer CA and
Morotti RA: Pathologic characteristics, natural history, and
prognostic implications of BRAF V600E mutation in pediatric thyroid
carcinoma. Pediatr Dev Pathol. 20:206–212. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Alzahrani AS, Murugan AK, Qasem E,
Alswailem M, Al-Hindi H and Shi Y: Single point mutations in
pediatric differentiated thyroid cancer. Thyroid. 27:189–196. 2017.
View Article : Google Scholar
|
|
88
|
Wasserman JD, Sabbaghian N, Fahiminiya S,
Chami R, Mete O, Acker M, Wu MK, Shlien A, de Kock L and Foulkes
WD: DICER1 mutations are frequent in adolescent-onset papillary
thyroid carcinoma. J Clin Endocrinol Metab. 103:2009–2015. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Romitti M, Ceolin L, Siqueira DR, Ferreira
CV, Wajner SM and Maia AL: Signaling pathways in follicular
cell-derived thyroid carcinomas (review). Int J Oncol. 42:19–28.
2013. View Article : Google Scholar
|
|
90
|
Rangel-Pozzo A, Sisdelli S, Cordiolo MIV,
Vaisman F, Caria P, Mai S and Cerutti JM: Genetic landscape of
papillary thyroid carcinoma and nuclear architecture: An overview
comparing pediatric and adult populations. Cancers (Basel).
12:E31462020. View Article : Google Scholar
|
|
91
|
Prasad PK, Mahajan P, Hawkins DS,
Mostoufi-Moab S and Venkatramani R: Management of pediatric
differentiated thyroid cancer: An overview for the pediatric
oncologist. Pediatr Blood Cancer. 67:e281412020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Brose MS, Nutting CM, Jarzab B, Elisei R,
Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R,
Shong YK, et al: Sorafenib in locally advanced or metastatic,
radioactive iodine-refractory, differentiated thyroid cancer: A
randomized, double-blind, Phase 3 trial. Lancet. 384:319–328. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Eng J Med. 372:621–630. 2015. View Article : Google Scholar
|
|
94
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Eficacy of Larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Laetsch TW, DuBois SG, Mascarenhas L,
Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL,
Rudzinski E, Feraco AM, et al: Larotrectinib for pediatric solid
tumours harbouring NTRK gene fusions: Phase 1 results from a
multicentre, open-label, phase 1/2 study. Lancet Oncol. 19:705–714.
2018. View Article : Google Scholar : PubMed/NCBI
|
